In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sangart's Series G round brings in $50mm

Executive Summary

Sangart Inc. (developing therapies that enhance oxygen delivery to deprived tissues) raised $50mm through its Series G round. Three existing investors, including leader Leucadia National Corp., received equity and warrants, and could commit to another $2.55mm in funding according to a Form D filed by the company. Sangart will use the proceeds to continue work on its two lead candidates--MP4OX for severe traumatic hemorrhage and MP4CO for sickle cell disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies